[Treatment and prognosis of retroperitoneal liposarcoma with multiple primary tumor].

Objective: To investigate the multiple origin of retroperitoneal liposarcoma and its postoperative prognosis. Methods: A total of 49 retroperitoneal liposarcoma patients underwent total (ipsilateral) retroperitoneal lipectomy in our center from May 2017 to December 2019 were recruited. Clinical data and the follow-up information were reviewed and the origin and prognosis were analyzed. Results: A total of 15 patients were pathologically diagnosed as multiple primary cancer (MPC), the incidence rate of retroperitoneal liposarcoma with MPC was 30.6% (15/49), while other 34 cases was non-MPC. The postoperative recurrence rates of patients with high differentiation and de-differentiation retroperitoneal liposarcoma were 31.8% and 44.4%, without significant difference (P>0.05). The postoperative recurrence rates of MPC and non-MPC were 40.0% and 38.2%, without significant difference (P>0.05). Five cases died within the follow-up. Conclusion: Retroperitoneal liposarcoma might origin form MPC, and total (ipsilateral) retroperitoneal lipectomy is recommended to reduce the recurrence rate.

Phase I and biodistribution study of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and ganciclovir administration in patients with head and neck cancer and other malignant tumors.

In this study, we investigated the safety and efficacy in cancer patients of a single intra-tumor injection of recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene (AdV/TK) followed by systemic administration of ganciclovir (GCV). In 18 patients with malignant tumors refractory to standard treatment, AdV/TK was injected on day 1 with dose escalation from 2.5 x 10(11) to 1 x 10(12) virus particles (VP), and GCV (5 mg kg(-1)) was delivered intravenously every 12 h from days 2 to 15. The most common treatment-related toxicities were transient fever (10/18) and local injection site reaction (10/18), and most adverse events were WHO grade I/II. Anti-adenovirus antibody levels increased continuously during treatment, but anti-HSV antibody levels remained stable. One patient had a PR at the injection site but PD was found in the primary site (lung cancer), one patient with fibrosarcoma of the neck had an MR, five patients had SD, and 10 patients had PD. In conclusion, AdV/TK followed by GCV can be administered safely to Chinese cancer patients, and achieved a local response with few environmental effects. Because the response was localized, single regional tumor relapse, especially after radiation, may be an indication for this suicide gene therapy.

Synthesis of the leu-enkephalin gene.

The synthesis of Leu-enkephalin gene by an alternative approach was described in this paper. The sequence of the synthetic gene, 26 base-pairs in length, was derived from the amino acid sequence of the hormone peptide Leu-enkephalin. It bears single-stranded cohesive termini for the restriction endonucleases EcoR I and BamH I so that it may be inserted into a pBR 322 plasmid. The 4 deoxyoligonucleotide fragments, varying in length from octanucleotide to octadecanucleotide, were synthesized by an improved phosphotriester method developed in our laboratory. All chemically synthetic fragments were pure and had the correct sequences. The assembly of the Leu-enkephalin gene was carried out in a one-step ligation reaction catalysed by T4-DNA ligase with good yield. Finally, the purified products from polyacrylamide gel electrophoresis had the correct joining-points as predicted.